South Korea’s Hyundai Motor has set up a branch in Thailand that will begin its operations on April 1 to gain a share of the local Japanese-dominated car market.
The Thai branch, called Hyundai Mobility Thailand, will be in charge of Hyundai Motor's vehicle sales, marketing, and after-sales services. It may consider building a local production facility depending on market demand.
Hyundai has shipped a small number of models, such as vans, to Thailand due to high import tariffs and other reasons.
Hyundai launched the multipurpose vehicle Stargazer at the Bangkok International Motor Show held from March 23-April 2 while planning to launch the compact Creta SUV in the second quarter.
The company also displayed the all-electric IONIQ 5 and IONIQ 6 models in the motor show.
In Southeast Asia, Hyundai also has branches in Indonesia and the Philippines.


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
Australian Household Spending Dips in December as RBA Tightens Policy
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Strength
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



